Clinical trial
Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With…
NCT00235352 · North Suffolk Mental Health Association, Other · Completed
Key facts
| NCT number | NCT00235352 |
|---|---|
| Title | Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia |
| Official title | A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia |
| Acronym | CX516 |
| Lead sponsor | North Suffolk Mental Health Association, Other |
| Collaborators | RespireRx Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | CX516 (Ampakine) |
| Enrollment | 105 |
| Start date | Feb 1, 2002 |
| Primary completion | Apr 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Oct 10, 2005 |
| Last update posted | Feb 26, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: